| Literature DB >> 16358364 |
Francesca Fallarino1, Paolo Puccetti.
Abstract
A series of recent studies, including an article in this issue of the European Journal of Immunology, have demonstrated that the administration of CpG-rich oligodeoxynucleotides (CpG-ODN) in experimental settings may lead to the activation of the immunosuppressive pathway of tryptophan catabolism, depending on several factors, including the route of CpG-ODN administration. These studies call attention to the need for a careful evaluation of the modalities of inclusion of CpG-ODN in vaccines for human use. At the same time, these studies may offer novel opportunities for use of CpG-ODN as immunosuppressive agents and may also lead to an improved understanding of the cellular events mediated by Toll-like receptor 9 signaling.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16358364 DOI: 10.1002/eji.200535667
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532